Quoin Pharmaceuticals
QNRX
4 hedge funds and large institutions have $81.1K invested in Quoin Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
56% more capital invested
Capital invested by funds: $52K → $81.1K (+$29K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
33% more funds holding
Funds holding: 3 → 4 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$172K |
| 2 |
Renaissance Technologies
New York
|
+$16.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.1K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$2.44K |
| 4 |
Morgan Stanley
New York
|
-$111 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $70K | +$172K | +352 | New |
|
|
2
Renaissance Technologies
New York
| $7K | +$16.1K | +33 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $3.12K | +$7.81K | +16 | New |
|
|
ASN
4
Advisory Services Network
Atlanta,
Georgia
| $951 | -$2.44K | -5 | -50% |
|
|
HNB
5
Huntington National Bank
Columbus,
Ohio
| $6 | – | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$31.1K | -52 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$15.1K | -25 | Closed |
|
|
8
Morgan Stanley
New York
| – | -$111 | – | – |
|
QNRX Hedge Fund Activity: Q1 2023 in Review
4 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2023, worth a combined $81.1K — up 56% from $52K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new QNRX positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $172K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $31.1K sold.
- 4 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $81.1K of Quoin Pharmaceuticals stock for Q1 2023, up 56% quarter-over-quarter.
- 3 funds opened new Quoin Pharmaceuticals positions in Q1 2023 and 2 closed out, a net change of +1 holder.
- The largest Quoin Pharmaceuticals buyer in Q1 2023 was Virtu Financial, an estimated $172K added.
- The largest Quoin Pharmaceuticals seller in Q1 2023 was Susquehanna International Group, an estimated $31.1K sold.
Based on aggregated 13F filings for Q1 2023.